1. Job Purpose / Mission
The Patient Advocacy Manager contributes to patient advocacy and patient policy activities across Merck Biopharma Japan’s Oncology, Fertility, and Rare Tumours businesses, working closely with the Head of Patient Advocacy.
As a member of the four-person Market Access & Public Affairs team, the role develops and executes patient-directed strategies that bring the patient voice into business and policy decisions while building trusted, compliant partnerships with patient organizations and other stakeholders.
The Patient Advocacy Manager reports to the Head of Patient Advocacy and works in a matrix with Japan business-unit leaders and colleagues in Medical Affairs, Regulatory, Legal & Compliance, Communications, Commercial, and Clinical Operations. The role also partners closely with global Patient Advocacy and cross-functional colleagues to align local priorities with global strategies.
The role has no direct reports and combines strategic planning, external engagement, policy advocacy, and hands-on execution.
2. Key Accountabilities & Responsibilities
2.1 Cross-Franchise Patient Advocacy Strategy and Implementation
Contribute to the development and implementation of an integrated patient advocacy strategy across Oncology, Fertility, and Rare Tumours, with franchise-specific priorities reflecting different patient journeys, unmet needs, and stakeholder landscapes.
Translate business and patient needs into annual advocacy plans, including priorities, milestones, KPIs, resource requirements, and budget, and maintain a clear view of the following year’s advocacy agenda.
Act as a strategic and operational business partner to the Oncology, Fertility, and Rare Tumours leadership teams, ensuring that patient advocacy is embedded in launch planning, lifecycle planning, and relevant brand or indication plans.
Prioritize activities across the three business areas while maintaining a coherent patient policy narrative and consistent standards of engagement.
Liaise with Global Government & Public Affairs and Global Patient Advocacy colleagues to ensure strategic alignment between local and global priorities.
2.2 Patient Organization Partnerships and Patient Insights
Build and maintain trusted, long-term, and compliant relationships with patient organizations and patient communities across Oncology, Fertility, and Rare Tumours.
Identify unmet needs of patients and caregivers, barriers to diagnosis and treatment, quality-of-life impacts, and gaps in information or support; convert these insights into practical recommendations for internal teams and external engagement.
Support capability-building and network development in rare-tumour communities where patient organizations are small, fragmented, or still emerging.
Ensure that patient insights inform clinical development, evidence generation, value communication, HTA and reimbursement materials, launch planning, disease awareness, and access dialogues.
2.3 Patient Policy and External Engagement
Contribute to day-to-day patient policy and advocacy engagement with patient organizations, academic societies, healthcare professionals, public institutions, policymakers, and other relevant stakeholders.
Coordinate senior-level outreach with the Head of Market Access & Public Affairs, including engagement with public authorities, Diet members’ offices where appropriate, and relevant policy forums.
Represent Merck Biopharma Japan in patient-focused, multi-stakeholder dialogues and contribute a balanced, evidence-based, patient-directed perspective to discussions on diagnosis, treatment access, care pathways, and outcomes.
Develop clear patient-directed narratives and materials that translate scientific, regulatory, health-system, and access topics into language that is accurate and accessible to patients and non-specialist stakeholders.
2.4 Specified Intractable Disease Designation Activities: Rare Tumours and Priority Conditions
Develop and execute advocacy activities supporting appropriate consideration of priority rare-tumour conditions, including desmoid tumours, in the context of Japan’s specified intractable disease designation process.
Translate patient insights into a practical rare-tumour patient advocacy roadmap, including patient advisory boards, internal Get Closer activities, patient testimonials and patient-voice materials, localized disease-support and shared-decision-making resources, and appropriate disease-awareness activities.
2.5 Drug Pricing and Reimbursement System Advocacy
Lead the patient advocacy contribution to policy discussions on Japan’s drug pricing, reimbursement, HTA, and patient-access systems, with particular attention to Oncology, Fertility, Rare Tumours, and other areas of high unmet need.
For priority launches and policy topics, coordinate patient-directed value-evidence and HTA-readiness activities, including the Japanese adaptation of value models, systematic evidence review, patient and physician insights, and disease-burden and societal-impact evidence such as surgery avoidance and productivity impact.
Liaise with Market Access & Pricing to monitor developments in the NHI drug-price system, reimbursement rules, HTA-related policy, rare-disease policy, and other reforms that may affect patient access and value recognition.
Develop evidence-based, patient-directed policy positions and advocacy messages, incorporating patient experience, disease burden, clinical context, and access needs.
Work with Market Access, Medical Affairs, Government Affairs, and industry-association colleagues to align positions, prepare stakeholder engagement, and support constructive dialogue with authorities and policymakers.
Ensure that patient perspectives are appropriately reflected in value dossiers, policy submissions, access strategies, and pricing or reimbursement discussions.
2.6 Industry Association Leadership, Primarily EFPIA
Participate in relevant pharmaceutical-industry activities, including initiatives led by EFPIA and JPMA, as well as broader industry-wide initiatives where relevant to and supportive of the patient advocacy and public affairs strategy.
Serve as the primary internal point of contact for patient advocacy and relevant patient policy activities conducted through EFPIA and its Japan-related forums or working groups, as applicable.
Represent or coordinate Merck Biopharma Japan’s participation in EFPIA working groups, consultations, position-paper development, evidence sharing, and joint advocacy initiatives, primarily in the areas of patient engagement, access, pricing, reimbursement, HTA, rare diseases, and healthcare policy.
Coordinate positions and messages with regional and global Patient Advocacy, Market Access, Public Affairs, and policy teams, ensuring appropriate local adaptation and internal alignment.
Bring relevant local learnings from patient advocacy plans and rare-tumour access priorities into EFPIA discussions, and translate agreed industry outputs into practical Japan plans and stakeholder engagement.
2.7 Annual Planning, Budget, and Execution
Develop and own the annual patient advocacy plan for assigned areas, including the forward plan for the following year, with clear objectives, deliverables, timelines, dependencies, and measures of success.
Maintain integrated multi-year roadmaps with phase-appropriate sequencing from stakeholder mapping and insight generation through co-creation, evidence development, policy engagement, implementation, and evaluation.
Manage approved budgets and external agency or partner relationships, ensuring effective prioritization and delivery across simultaneous projects.
Provide regular progress updates, risk assessments, and recommendations to the Head of Patient Advocacy and relevant business partners.
Capture learnings and demonstrate the impact of patient advocacy and policy activities through qualitative and quantitative reporting.
3. Key Interfaces
Internal
Market Access & Public Affairs and the four-person team
Business-unit heads and leadership teams for Oncology, Fertility, and Rare Tumours
Medical Affairs
Regulatory
Commercial
Clinical Operations
Communications
Legal & Compliance
Regional and Global Patient Advocacy, Market Access, and Public Affairs teams
External
Patient organizations and patient communities
Patients and caregivers
Academic societies and clinical experts
MHLW- and PMDA-related stakeholders
Diet members’ offices, where appropriate
EFPIA and relevant working groups
JPMA and other industry associations
Policymakers
Healthcare media, in coordination with Communications
External agencies and partners